Over the course of the projection period, prominent players are anticipated to step up their research and development efforts. For instance, the Phase I research of RBM007 for the treatment of achondroplasia was completed, according to an announcement made by RIBOMIC, a clinical stage pharmaceutical business with a focus on aptamer therapies, in May 2021. The aim of the research was to assess the pharmacokinetics, safety, and tolerability of RBM007 for achondroplasia.
Request Sample Report (Including Full TOC, Table & Figures) @
https://www.coherentmarketinsights.com/insight/request-sample/4161
The financial standing of companies in all industries, including the private healthcare sector, has been harmed by the COVID-19 epidemic and lockdowns in several nations throughout the world. Due to rigorous lockdown in certain areas, the COVID-19 pandemic has affected the whole supply chain of the healthcare business. One area where the COVID-19 epidemic has had a big influence is private healthcare.
Due to the limitations during the clinical trial research of new products, the influence of the coronavirus (COVID-19) pandemic is anticipated to restrain the growth of the global achondroplasia market over the forecast period. For instance, on April 8, 2020, BioMarin Pharmaceutical Inc., a biotechnology company with headquarters in the United States, released a report on the company’s clinical development programme for achondroplasia during the COVID-19 pandemic. The report stated that as more COVID-19 cases were confirmed, the company and the participants in the BioMarin clinical studies encountered difficulties. The most difficult parts of the current COVID-19 pandemic, which is harming the health and livelihoods of many people throughout the world, were the safety and well-being of the research participants and medical professionals.
Additionally, during the course of the projected period, the market is anticipated to rise due to the rising prevalence of achondroplasia. For instance, 350 infants are thought to be born in Europe each year with achondroplasia, according to information released by the European Medicines Agency in June 2021.
Key Takeaways
Due to an increase in research & development initiatives by the major market players, the worldwide achondroplasia market is anticipated to have a CAGR of 36.0% during the projected period. For instance, the American multinational pharmaceutical and biotechnology company Pfizer Inc. reported in December 2020 that the first patients had received their doses in the global Phase 2 multiple dose, randomised study to evaluate the efficacy of recifercept, safety, pharmacokinetics, and, tolerability, a soluble recombinant human fibroblast growth factor receptor 3 (FGFR3) decoy, in children with achondroplasia.
Due to the rising incidence of achondroplasia, the oral segment is anticipated to have a leading position in the worldwide achondroplasia market in terms of method of administration throughout the forecast period. For instance, achondroplasia is the most prevalent cause of disproportionately small height, with 3-5 children in Western Australia being born with the disease each year, according to statistics released by the Government of Western Australia Child and Adolescent Health Service in March 2021.
Due to the increasing research and development activities by the key players in the region for the development and launch of novel therapeutics for the treatment of patients suffering from achondroplasia, North America is anticipated to hold the largest market share among all regions over the forecast period. For instance, QED Therapeutics, a division of BridgeBio Pharma, Inc., said in July 2020 that the first patient with achondroplasia had received a dosage of infigratinib, an experimental treatment for the condition. In the PROPEL 2 Phase 2 clinical study, the orally accessible small drug infigratinib addresses the excessive activation of fibroblast growth factor receptor 3 (FGFR3).
Request PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/4161
Major companies active in the global achondroplasia market include Xiamen Amoytop Biotech Co., Ltd., BioMarin, Novartis AG, RIBOMIC, Ipsen Pharma, Eli Lilly and Company, Ascendis Pharma A/S, Teva Pharmaceutical Industries Ltd., BridgeBio Pharma, Inc., ProLynx Inc., Pfizer, Inc., VIVUS LLC., PhaseBio Pharmaceuticals, Inc., KVK TECH, INC., SiSaf, Novo Nordisk A/S, F. JCR Pharmaceuticals Co., Ltd, Hoffmann-La Roche Ltd, and LG Chem, Ferring B.V.
Reasons to buy this Achondroplasia Treatment Market Report
☑ It attempts an analysis of the competing scenario.
☑ The current and exceptional product revenue market.
☑ An in-depth data on the regional investigation and competitive landscape structure.
☑ It benefits in creating an awareness of the important key product segments.
☑ The marketing strategies, opportunities, and development factors are explained.
☑ Achondroplasia Treatment market size estimation and recent advancements in the industry are explained.
Buy this Complete Business Report @
https://www.coherentmarketinsights.com/insight/buy-now/4161
Table of Content
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Treatment Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Key Developments
- Treatment Approaches for Achondroplasia
- Merger, Acquisition & Agreements
- Pipeline Analysis
- Regulatory Scenario
- PEST Analysis
- Epidemiology
- Therapeutics Overview
- Market Dynamics
- Global Achondroplasia Market- Impact of Coronavirus (Covid-19) Pandemic
- Economic Impact
- COVID-19 Epidemiology
- Research and Development
- Global Achondroplasia Market, By Treatment Type, 2017 – 2030, (US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Vosoritide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Human Growth Hormone
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Overview
- Global Achondroplasia Market, By Route of Administration, 2017 – 2030, (US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Parenteral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Overview
- Global Achondroplasia Market, By Distribution Channel, 2017 – 2030, (US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Overview
- Global Achondroplasia Market, By Region, 2017 – 2030, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 – 2030
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
- UK
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 – 2030, (US$ Million)
- North Africa
- Central Africa
- South Africa
- Introduction
- Competitive Landscape
- BioMarin
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- RIBOMIC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Ascendis Pharma A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- BridgeBio Pharma, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- PhaseBio Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- SiSaf
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novo Nordisk A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- F. Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- LG Chem
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Ferring B.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- JCR Pharmaceuticals Co., Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- KVK TECH, INC.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- VIVUS LLC.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- ProLynx Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Ipsen Pharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Xiamen Amoytop Biotech Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- BioMarin
- Section
- Research Methodology
- About Us
About Coherent Market Insights
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837